Junping Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Junping Li has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
Hong Hu
Department of Radiology, Xiangyang No. 1 People's Hospital, Hubei University of Medicine, Xiangyang, Hubei 441000, P.R. China
5 shared publicationsJie Tian
Department of Radiology, Postgraduate Union Training Base of Xiangyang No. 1 People's Hospital, School of Medicine, Wuhan University of Science and Technology, Xiangyang, Hubei 441000, P.R. China
2 shared publicationsPeng Mo
Department of Radiotherapy, 900th Hospital of Joint Logistics Support Force, Fujian Medical University, Fuzhou, China
2 shared publicationsSiyi Chen
Department of Radiology, Xiangyang No. 1 People's Hospital, Hubei University of Medicine, Xiangyang, Hubei 441000, P.R. China
2 shared publicationsXian Zhang
Department of Radiology, Xiangyang No. 1 People’s Hospital, Hubei University of Medicine, Xiangyang, China
2 shared publicationsYi Li
Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
2 shared publications
Latest Publications
- Open Access
- 1 May 2026
- Published by AME Publishing Company in Translational Lung Cancer Research
- Vol. 15 (5) , 134
Development and validation of a nomogram for predicting overall survival in small cell lung cancer: a multicenter analysis integrating multimodal therapy and molecular pathology
Background: Small cell lung cancer (SCLC) is an aggressive malignancy with heterogeneous survival outcomes. Conventional staging systems do not fully capture the influence of multimodal treatment strategies or molecular pathological characteristics on prognosis. However, prognostic models integrating treatment modalities with molecular pathology remain limited in SCLC. This study aimed to evaluate the survival impact of multimodal treatments and develop a nomogram incorporating clinical and molecular features for individualized prognostic prediction. Methods: This retrospective multicenter study included patients diagnosed with SCLC between 2020 and 2024 at three medical centers. Patients from two centers were randomly divided into a derivation cohort (70%) and an internal validation cohort (30%), while patients from the third center served as an independent external validation cohort. Overall survival (OS) was the primary endpoint. Candidate predictors were selected using the Boruta algorithm and the least absolute shrinkage and selection operator (LASSO) regression, and a multivariable Cox proportional hazards model was used to construct a nomogram for predicting 1-year OS. Model performance was evaluated using time-dependent receiver operating characteristic (ROC) curves, calibration plots, and decision curve analysis (DCA), and was further compared with the tumor, node, metastasis (TNM) staging system and Veterans Administration Lung Study Group (VALG) staging system. Results: A total of 728 patients were included and assigned to the derivation cohort (n=468), internal validation cohort (n=200), and external validation cohort (n=60). A nomogram incorporating pathological score, therapy, clinical T stage, clinical N stage, and TNM clinical stage was developed. The nomogram showed better discrimination than the TNM and VALG staging systems in the derivation cohort, with an area under the ROC curve (AUC) of 0.801 and a 95% confidence interval (CI) of 0.758–0.844, versus 0.664 (95% CI: 0.609–0.719) and 0.603 (95% CI: 0.051–0.655), respectively; similar results were observed in the internal validation cohort [0.800 (95% CI: 0.734–0.866) vs. 0.649 (95% CI: 0.560–0.738) and 0.569 (95% CI: 0.488–0.650)] and the external validation cohort [0.776 (95% CI: 0.646–0.906) vs. 0.611 (95% CI: 0.460–0.762) and 0.593 (95% CI: 0.462–0.725)]. Calibration curves showed good agreement between predicted and observed 1-year OS, and DCA demonstrated favorable clinical utility across all cohorts. Conclusions: Multimodal treatment strategies were associated with survival in advanced SCLC. The proposed nomogram improved individualized 1-year survival prediction beyond conventional staging systems in SCLC. By integrating treatment-related and pathological information with clinical staging variables, this approach may support risk stratification, treatment intensity, and inform follow-up planning in clinical practice.
- 1 May 2026
- Published by AME Publishing Company in Translational Lung Cancer Research
- Vol. 15 (5) , 134
Open AccessDevelopment and validation of a nomogram for predicting overall survival in small cell lung cancer: a multicenter analysis integrating multimodal therapy and molecular pathology
Background: Small cell lung cancer (SCLC) is an aggressive malignancy with heterogeneous survival outcomes. Conventional staging systems do not fully capture the influence of multimodal treatment strategies or molecular pathological characteristics on prognosis. However, prognostic models integrating treatment modalities with molecular pathology remain limited in SCLC. This study aimed to evaluate the survival impact of multimodal treatments and develop a nomogram incorporating clinical and molecular features for individualized prognostic prediction. Methods: This retrospective multicenter study included patients diagnosed with SCLC between 2020 and 2024 at three medical centers. Patients from two centers were randomly divided into a derivation cohort (70%) and an internal validation cohort (30%), while patients from the third center served as an independent external validation cohort. Overall survival (OS) was the primary endpoint. Candidate predictors were selected using the Boruta algorithm and the least absolute shrinkage and selection operator (LASSO) regression, and a multivariable Cox proportional hazards model was used to construct a nomogram for predicting 1-year OS. Model performance was evaluated using time-dependent receiver operating characteristic (ROC) curves, calibration plots, and decision curve analysis (DCA), and was further compared with the tumor, node, metastasis (TNM) staging system and Veterans Administration Lung Study Group (VALG) staging system. Results: A total of 728 patients were included and assigned to the derivation cohort (n=468), internal validation cohort (n=200), and external validation cohort (n=60). A nomogram incorporating pathological score, therapy, clinical T stage, clinical N stage, and TNM clinical stage was developed. The nomogram showed better discrimination than the TNM and VALG staging systems in the derivation cohort, with an area under the ROC curve (AUC) of 0.801 and a 95% confidence interval (CI) of 0.758–0.844, versus 0.664 (95% CI: 0.609–0.719) and 0.603 (95% CI: 0.051–0.655), respectively; similar results were observed in the internal validation cohort [0.800 (95% CI: 0.734–0.866) vs. 0.649 (95% CI: 0.560–0.738) and 0.569 (95% CI: 0.488–0.650)] and the external validation cohort [0.776 (95% CI: 0.646–0.906) vs. 0.611 (95% CI: 0.460–0.762) and 0.593 (95% CI: 0.462–0.725)]. Calibration curves showed good agreement between predicted and observed 1-year OS, and DCA demonstrated favorable clinical utility across all cohorts. Conclusions: Multimodal treatment strategies were associated with survival in advanced SCLC. The proposed nomogram improved individualized 1-year survival prediction beyond conventional staging systems in SCLC. By integrating treatment-related and pathological information with clinical staging variables, this approach may support risk stratification, treatment intensity, and inform follow-up planning in clinical practice.
- Open Access
- 8 April 2026
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 31 (6) , 1-5
Retroperitoneal ovarian venous hemangioma: A case report
Retroperitoneal venous hemangioma is a rare vascular malformation. The present study reports a unique case of a 68-year-old female with a retroperitoneal ovarian venous hemangioma that was surgically resected. Computed tomography and magnetic resonance imaging showed a retroperitoneal mass anterior to the left kidney. Enhanced imaging revealed a close relationship between the mass and surrounding vessels, suggesting a retroperitoneal vascular neoplasm. Histopathological examination of the tissue after complete surgical resection confirmed the diagnosis of a retroperitoneal ovarian venous hemangioma. This case provides crucial insights for clinicians to enhance their understanding of ovarian venous hemangioma through the integration of multimodal imaging characteristics and pathological evidence, thereby contributing to the reduction of misdiagnosis in clinical practice.
- 8 April 2026
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 31 (6) , 1-5
Open AccessRetroperitoneal ovarian venous hemangioma: A case report
Retroperitoneal venous hemangioma is a rare vascular malformation. The present study reports a unique case of a 68-year-old female with a retroperitoneal ovarian venous hemangioma that was surgically resected. Computed tomography and magnetic resonance imaging showed a retroperitoneal mass anterior to the left kidney. Enhanced imaging revealed a close relationship between the mass and surrounding vessels, suggesting a retroperitoneal vascular neoplasm. Histopathological examination of the tissue after complete surgical resection confirmed the diagnosis of a retroperitoneal ovarian venous hemangioma. This case provides crucial insights for clinicians to enhance their understanding of ovarian venous hemangioma through the integration of multimodal imaging characteristics and pathological evidence, thereby contributing to the reduction of misdiagnosis in clinical practice.
- Open Access
- 1 May 2025
- Published by AME Publishing Company in Translational Lung Cancer Research
- Vol. 14 (5) , 1582-1595
Change of bone mineral density as a prognostic marker in small cell lung cancer treated with immune checkpoint inhibitors: a multicenter retrospective study
Background: Changes in bone mineral density (BMD) are recognized as an independent predictor of survival in a variety of diseases. However, the prognostic value of BMD in small cell lung cancer (SCLC) patients treated with immune checkpoint inhibitors (ICIs) is not well understood. This study aimed to explore the prognostic ability of change in bone mineral density (ΔBMD) on the survival of SCLC patients receiving ICIs. Methods: A total of 300 SCLC patients receiving ICIs from three hospitals were enrolled and underwent non-enhanced thoracic computed tomography (CT) before and after treatment. Overall survival (OS) and progression-free survival (PFS) were analyzed using Cox regression models and Kaplan-Meier survival curves. A nomogram model based on independent prognostic factors was developed using multivariate Cox proportional hazards analysis. The predictive efficacy and clinical benefit of the nomogram were evaluated using the time-dependent area under the receiver operating characteristic (ROC) curve and calibration curves. Results: Lower ΔBMD was associated with shorter PFS and OS. ΔBMD was identified as an independent prognostic factor affecting OS (risk ratios =0.461; PConclusions: Lower ΔBMD is correlated with poorer clinical outcomes in SCLC patients undergoing treatment with ICIs.
- 1 May 2025
- Published by AME Publishing Company in Translational Lung Cancer Research
- Vol. 14 (5) , 1582-1595
Open AccessChange of bone mineral density as a prognostic marker in small cell lung cancer treated with immune checkpoint inhibitors: a multicenter retrospective study
Background: Changes in bone mineral density (BMD) are recognized as an independent predictor of survival in a variety of diseases. However, the prognostic value of BMD in small cell lung cancer (SCLC) patients treated with immune checkpoint inhibitors (ICIs) is not well understood. This study aimed to explore the prognostic ability of change in bone mineral density (ΔBMD) on the survival of SCLC patients receiving ICIs. Methods: A total of 300 SCLC patients receiving ICIs from three hospitals were enrolled and underwent non-enhanced thoracic computed tomography (CT) before and after treatment. Overall survival (OS) and progression-free survival (PFS) were analyzed using Cox regression models and Kaplan-Meier survival curves. A nomogram model based on independent prognostic factors was developed using multivariate Cox proportional hazards analysis. The predictive efficacy and clinical benefit of the nomogram were evaluated using the time-dependent area under the receiver operating characteristic (ROC) curve and calibration curves. Results: Lower ΔBMD was associated with shorter PFS and OS. ΔBMD was identified as an independent prognostic factor affecting OS (risk ratios =0.461; PConclusions: Lower ΔBMD is correlated with poorer clinical outcomes in SCLC patients undergoing treatment with ICIs.
- 21 April 2025
- Published by Wiley in Journal of Magnetic Resonance Imaging
Habitat Radiomics Based on Dynamic Contrast‐Enhanced Magnetic Resonance Imaging for Assessing Axillary Lymph Node Burden in Clinical T1–T2 Stage Breast Cancer: A Multicenter and Interpretable Study
Background: Axillary lymph node burden(ALNB) is a critical factor in determining treatment strategies for clinical T1–T2 (cT1–T2) stage breast cancer. However, as ALNB assessment relies on invasive procedures, exploring non‐invasive methods is essential.Purpose: To develop and validate a habitat radiomics model for assessing ALNB in cT1–T2 breast cancer, incorporating radiogenomic data to improve interpretability.Study Type: Retrospective.Population: 468 patients with cT1–T2 stage breast cancer from two institutions and The Cancer Imaging Archive (TCIA) and The Cancer Genome Atlas (TCGA)‐Breast Invasive Carcinoma (BRCA) were included. The cohort was divided into training (n = 173), internal validation (n = 58), external validation (n = 130), and TCGA‐BRCA sets (n = 107). Patients were categorized into high nodal burden (HNB; > 3 positive lymph nodes) and non‐HNB (≤ 3 positive lymph nodes) groups.Field Strength/Sequence: 1.5‐T MRI and 3.0‐T MRI, and three‐dimensional dynamic contrast‐enhanced T1‐weighted gradient‐echo sequences.Assessment: Two logistic regression models were developed using habitat‐based and clinical features. Model performance was evaluated using the AUC. SHapley Additive exPlanations (SHAP) analysis was employed to identify key features. Radiogenomic analysis, including gene set enrichment and drug sensitivity assessments, was conducted using transcriptomic data from the TCGA‐BRCA set.Statistical Tests: Pearson correlation, Mann–Whitney U, genetic algorithm, logistic regression, AUC analysis, delong test, and SHAP analysis. A p‐value < 0.05 was considered statistically significant.Results: The Habitat model outperformed the Clinical model (AUCs: 0.840–0.932 vs. 0.558–0.673). The SHAP analysis was used to rank feature importance, with subregion 3 showing the highest average SHAP value. Radiogenomic analysis indicated upregulation of the KEGG ribosome pathway in the HNB group and identified differential drug sensitivity profiles among risk groups.Data Conclusion: The Habitat model has the potential to assess ALNB in cT1–T2 breast cancer and assist radiologists in axillary diagnosis, which may help reduce the need for unnecessary ALN dissection.Evidence Level: 3.Technical Efficacy: Stage 2.
- 21 April 2025
- Published by Wiley in Journal of Magnetic Resonance Imaging
Habitat Radiomics Based on Dynamic Contrast‐Enhanced Magnetic Resonance Imaging for Assessing Axillary Lymph Node Burden in Clinical T1–T2 Stage Breast Cancer: A Multicenter and Interpretable Study
Background: Axillary lymph node burden(ALNB) is a critical factor in determining treatment strategies for clinical T1–T2 (cT1–T2) stage breast cancer. However, as ALNB assessment relies on invasive procedures, exploring non‐invasive methods is essential.Purpose: To develop and validate a habitat radiomics model for assessing ALNB in cT1–T2 breast cancer, incorporating radiogenomic data to improve interpretability.Study Type: Retrospective.Population: 468 patients with cT1–T2 stage breast cancer from two institutions and The Cancer Imaging Archive (TCIA) and The Cancer Genome Atlas (TCGA)‐Breast Invasive Carcinoma (BRCA) were included. The cohort was divided into training (n = 173), internal validation (n = 58), external validation (n = 130), and TCGA‐BRCA sets (n = 107). Patients were categorized into high nodal burden (HNB; > 3 positive lymph nodes) and non‐HNB (≤ 3 positive lymph nodes) groups.Field Strength/Sequence: 1.5‐T MRI and 3.0‐T MRI, and three‐dimensional dynamic contrast‐enhanced T1‐weighted gradient‐echo sequences.Assessment: Two logistic regression models were developed using habitat‐based and clinical features. Model performance was evaluated using the AUC. SHapley Additive exPlanations (SHAP) analysis was employed to identify key features. Radiogenomic analysis, including gene set enrichment and drug sensitivity assessments, was conducted using transcriptomic data from the TCGA‐BRCA set.Statistical Tests: Pearson correlation, Mann–Whitney U, genetic algorithm, logistic regression, AUC analysis, delong test, and SHAP analysis. A p‐value < 0.05 was considered statistically significant.Results: The Habitat model outperformed the Clinical model (AUCs: 0.840–0.932 vs. 0.558–0.673). The SHAP analysis was used to rank feature importance, with subregion 3 showing the highest average SHAP value. Radiogenomic analysis indicated upregulation of the KEGG ribosome pathway in the HNB group and identified differential drug sensitivity profiles among risk groups.Data Conclusion: The Habitat model has the potential to assess ALNB in cT1–T2 breast cancer and assist radiologists in axillary diagnosis, which may help reduce the need for unnecessary ALN dissection.Evidence Level: 3.Technical Efficacy: Stage 2.
- Open Access
- 27 January 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-9
Longitudinal MRI evaluation of the efficacy of non-enhanced lung cancer brain metastases
Brain metastases (BM) are the most prevalent intracranial malignancies. Approximately 30–40% of cancer patients develop BM at some stage of their illness, presenting with a high incidence and poor prognosis. Our clinical findings indicate a significant disparity in the efficacy between non-enhanced and enhanced lung cancer BM. Therefore, the aim of this study is to conduct a longitudinal MRI evaluation of the therapeutic effect of non-enhanced lung cancer BM, thereby enabling improved efficacy prediction and more personalized treatment plans. We conducted a retrospective analysis of clinical and imaging data from 72 patients with lung cancer BM. Exclusion criteria included participants with a history of primary brain tumors, other malignancies, or neurological symptoms. We performed a longitudinal MRI evaluation of 8 patients with non-enhanced BM who met the eligibility criteria. The response to systemic therapy was locally assessed using the Neuro-Oncology response assessment criteria (RANO 2.0). A total of 8 patients were included in this study, comprising 4 cases of non-enhanced BM and 4 cases featuring both enhanced and non-enhanced BM. The median follow-up time for non-enhanced BM was 19 months, with a disease control rate of 50%. In contrast, the median progression-free follow-up time for enhanced BM was 35.5 months, yielding a disease control rate of 100%. After standardized treatment in accordance with clinical guidelines, patients with enhanced BM exhibited significantly better therapeutic outcomes than those with non-enhanced BM. Cases 1–4 demonstrated non-enhanced or mildly circular-enhanced lung cancer BM, with the sizes of all 4 lesions increasing by over 60% within approximately one year, indicating disease progression. In cases 5–8, each patient presented with two lesions: enhanced (Foci 1) and non-enhanced (Foci 2) BM. Comparative analysis of Foci 1 and Foci 2 revealed significantly weaker treatment responses in non-enhanced lesions (Patients 7–8), with Patient 5 exhibiting disease progression without any response. This study demonstrates that, following standardized treatment protocols aligned with clinical guidelines, the therapeutic effect of non-enhanced lung cancer BM is inferior to that of enhanced BM. Evaluating the enhancement type of lung cancer BM is essential for efficacy prediction and holds important implications for treatment guidance.
- 27 January 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-9
Open AccessLongitudinal MRI evaluation of the efficacy of non-enhanced lung cancer brain metastases
Brain metastases (BM) are the most prevalent intracranial malignancies. Approximately 30–40% of cancer patients develop BM at some stage of their illness, presenting with a high incidence and poor prognosis. Our clinical findings indicate a significant disparity in the efficacy between non-enhanced and enhanced lung cancer BM. Therefore, the aim of this study is to conduct a longitudinal MRI evaluation of the therapeutic effect of non-enhanced lung cancer BM, thereby enabling improved efficacy prediction and more personalized treatment plans. We conducted a retrospective analysis of clinical and imaging data from 72 patients with lung cancer BM. Exclusion criteria included participants with a history of primary brain tumors, other malignancies, or neurological symptoms. We performed a longitudinal MRI evaluation of 8 patients with non-enhanced BM who met the eligibility criteria. The response to systemic therapy was locally assessed using the Neuro-Oncology response assessment criteria (RANO 2.0). A total of 8 patients were included in this study, comprising 4 cases of non-enhanced BM and 4 cases featuring both enhanced and non-enhanced BM. The median follow-up time for non-enhanced BM was 19 months, with a disease control rate of 50%. In contrast, the median progression-free follow-up time for enhanced BM was 35.5 months, yielding a disease control rate of 100%. After standardized treatment in accordance with clinical guidelines, patients with enhanced BM exhibited significantly better therapeutic outcomes than those with non-enhanced BM. Cases 1–4 demonstrated non-enhanced or mildly circular-enhanced lung cancer BM, with the sizes of all 4 lesions increasing by over 60% within approximately one year, indicating disease progression. In cases 5–8, each patient presented with two lesions: enhanced (Foci 1) and non-enhanced (Foci 2) BM. Comparative analysis of Foci 1 and Foci 2 revealed significantly weaker treatment responses in non-enhanced lesions (Patients 7–8), with Patient 5 exhibiting disease progression without any response. This study demonstrates that, following standardized treatment protocols aligned with clinical guidelines, the therapeutic effect of non-enhanced lung cancer BM is inferior to that of enhanced BM. Evaluating the enhancement type of lung cancer BM is essential for efficacy prediction and holds important implications for treatment guidance.
- Open Access
Charcot arthropathy of the knee accompanied by tethered cord syndrome and lumbosacral fur sinus